Larvol Delta - Coya-Therapeutics-Announces-Positive-Results-of-a-DoubleBlind-Study-of-Subcutaneous-LowDose-Interleukin2-LD-IL2-in-Alzheimers-Disease-AD-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid-Spain

COYA 301 - Coya Therap

https://www.businesswire.com/news/home/20241029490704/en/Coya-Therapeutics-Announces-Positive-Results-of-a-Double-Blind-Study-of-Subcutaneous-Low-Dose-Interleukin-2-LD-IL-2-in-Alzheimer%E2%80%99s-Disease-AD-Presented-at-the-Clinical-Trials-on-Alzheimer%E2%80%99s-Disease-Conference-CTAD24-in-Madrid-Spain

Oct 29, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next